The United States of America, As Represented by the Secretary, Department of Health and Human Services

The University of North Carolina at Chapel Hill

University of Kansas

Geneuro Sa

Joseph Perry Steiner

Noel Terrence Southall

Xin Hu

Kevin Frankowski

Marc Ferrer

Warren S Weiner

Avindra Nath

David Robert Sibley

Hervé Perron

Julie Medina

Jeffrey Aubé

R Benjamin Free

Wenxue Li

Amy Elizabeth Moritz

Myound-Hwa Lee

Myoung-Hwa Lee

Jeffrey AubÉ

The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof

Selective D3 dopamine receptor agonists and methods of their use

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R, R, R, and Rare defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

Selective Ddopamine receptor agonists and methods of their use

The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or is therapy.

Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis

The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.

Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody

Growing community of inventors

Mounty Airy, MD, United States of America

Joseph Perry Steiner